Monty Rakusen/DigitalVision via Getty Images ClearPoint Neuro's ( CLPT ) stock has fallen significantly in early 2026, driven by weak financial guidance and increased uncertainty regarding the FDA's attitude towards gene therapies for rare diseases. Softer growth expectations for 2026 are largely the result of the preclinical CRO facility launch pushing out and reduced expectations for revenue fro...
Monty Rakusen/DigitalVision via Getty Images ClearPoint Neuro's ( CLPT ) stock has fallen significantly in early 2026, driven by weak financial guidance and increased uncertainty regarding the FDA's attitude towards gene therapies for rare diseases. Softer growth expectations for 2026 are largely the result of the preclinical CRO facility launch pushing out and reduced expectations for revenue from biopharma partners' commercializing their therapies. I previously suggested that ClearPoint was positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. The stock is down around 17% since then, although it dropped as much as 40%. Current concerns are short-sighted, though, as ClearPoint has a strong competitive position, and a step change in revenue remains likely. While AMT-130's near-term fate remains uncertain, Parkinson's and epilepsy partners are far more important to ClearPoint's future. These programs are in Phase III trials at the moment and do not have the same trial design concerns as rare disease partner programs. It may make time, but I continue to believe that ClearPoint's stock will move significantly higher within the next few years. Market Conditions The most important market developments for ClearPoint in recent months relate to the FDA's attitude towards rare disease therapies. Regenxbio's gene therapy for Hunter syndrome was rejected by the FDA in February, with the use of a natural history control arm and a biomarker as a surrogate endpoint cited as concerns. MPS II is a rare condition, meaning any associated revenue would likely be inconsequential for ClearPoint. The decision is indicative of the regulatory environment, though. There was also a fairly public spat over uniQure's ( QURE ) trial design and the quality of the data generated. By March, the FDA was insisting on a randomized , double-blind, sham surgery–controlled. While this may be scientific best practice, in this scenario ...
UBS Group AG Chief Financial Officer Todd Tuckner said that recent developments have cooled excitement among the lender’s rich clients about private credit, adding to the challenges facing the asset class. “Interest in private credit among our wealthy clients has been more measured in the current environment,” Tuckner said on an analyst call Wednesday. That’s “clearly reflecting macro uncertainty ...
UBS Group AG Chief Financial Officer Todd Tuckner said that recent developments have cooled excitement among the lender’s rich clients about private credit, adding to the challenges facing the asset class. “Interest in private credit among our wealthy clients has been more measured in the current environment,” Tuckner said on an analyst call Wednesday. That’s “clearly reflecting macro uncertainty and a preference for liquidity and capital preservation.” The comments highlight some of the growing pains facing the $1.8 trillion private credit industry after years of rapid expansion. In recent months, fears that artificial intelligence looks set to disrupt the private equity-backed software businesses that borrow heavily from direct lenders has led investors to step up redemption requests at some of the largest non-traded private credit investment vehicles. Read More: Direct Lending Fundraising Hits Three-Year Low in First Quarter Tuckner also said that private credit remains a “very modest portion” of the bank’s balance sheet, with private credit funds accounting for around 50 to 60 basis points of its total leverage exposure. There have been increasing questions about the exposure of banks to the asset class. Deutsche Bank AG in March flagged a €26 billion ($30.4 billion) exposure to private credit. CFO Raja Akram said in a Bloomberg TV interview on Wednesday that private credit continues to be a “non-story” for the lender. On a call afterwards he added that the firm continues “to tighten our underwriting standards in the current environment, being super selective about who we lend money to.” Read More: Deutsche Bank Flags $30 Billion Exposure to Private Credit
New Zealand officials rejected on Wednesday an application to install a statue commemorating so-called “comfort women” enslaved by Japan before and during World War II after Tokyo suggested it could harm diplomatic relations. Japan forced up to 200,000 women from Korea, China and Southeast Asia into sexual slavery from 1932 until 1945 and the issue remains a sore point in Tokyo’s relations with it...
New Zealand officials rejected on Wednesday an application to install a statue commemorating so-called “comfort women” enslaved by Japan before and during World War II after Tokyo suggested it could harm diplomatic relations. Japan forced up to 200,000 women from Korea, China and Southeast Asia into sexual slavery from 1932 until 1945 and the issue remains a sore point in Tokyo’s relations with its neighbours. The Korean Garden Trust had sought to install a statue honouring the survivors at...